SymbioTec (Germany) Overview

  • Founded
  • 1999
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $14.4M
Latest Deal Amount

SymbioTec (Germany) General Information


Developer of medicines for cancer and infectious diseases. The company develops and markets pharmaceutical products for therapy and diagnostics of life-threatening diseases. It produces and sales medicines focused on treatment of acute lymphocytic and myeloid leukaemia.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Science Park Saar 1
  • 66123 Saarbrücken
  • Germany
+49 0681 00000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

SymbioTec (Germany) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 17-Jan-2012 $14.4M 00.00 000.00 Completed Generating Revenue
3. Later Stage VC 15-Mar-2011 00.00 Completed Generating Revenue
2. Later Stage VC 18-Aug-2009 $1.4M $1.4M Completed Generating Revenue
1. Early Stage VC 01-Jan-2001 Completed Startup
To view SymbioTec (Germany)’s complete valuation and funding history, request access »

SymbioTec (Germany) Executive Team (2)

Name Title Board Seat Contact Info
Volker Rusch Co-Founder
Michael Zeppezauer Co-Founder
To view SymbioTec (Germany)’s complete executive team members history, request access »

SymbioTec (Germany) Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Gradus Venture Venture Capital Minority 000 0000 000000 0
Human Stem Cells Institute Corporation Minority 000 0000 000000 0
To view SymbioTec (Germany)’s complete investors history, request access »